Belarus vs East Timor: Statin use vs. average non-HDL cholesterol levels
Belarus
3.2
in 2018
East Timor
3.2
in 2018
Belarus rank
118th
East Timor rank
118th
Statin use vs. average non-HDL cholesterol levels over time
- Belarus
- East Timor
How they compare
Belarus currently reports 3.2 against 3.2 in East Timor, a difference of 0.
The two have swapped places 1 time across 39 shared years of data; in 1980 it was Belarus ahead.
Belarus ranks 118th and East Timor ranks 118th of 191 countries.
Belarus has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Belarus | East Timor | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 4 | 2.68 | 1.32 | Belarus |
| 1990s | 3.92 | 2.89 | 1.03 | Belarus |
| 2000s | 3.69 | 3.06 | 0.63 | Belarus |
| 2010s | 3.39 | 3.16 | 0.2333 | Belarus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Belarus or East Timor?
- Belarus, at 3.2 against 3.2 in East Timor as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Belarus and East Timor?
- 0, with Belarus ahead.
- How many years of comparable data are there for Belarus and East Timor?
- 39 years are reported by both, from 1980 to 2018.
- How do Belarus and East Timor rank globally for statin use vs. average non-hdl cholesterol levels?
- Belarus ranks 118th and East Timor ranks 118th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.